Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
ID: 351472Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351472

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-088.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can enhance the understanding of biological processes related to mental health, aging, addiction, and eye diseases. Applicants are expected to have validated starting compounds for chemical optimization and bioassays for testing new analog compounds, with a focus on projects that provide insights into disease-related biological targets and mechanisms. This grant opportunity is open to a wide range of eligible applicants, including higher education institutions, nonprofit organizations, and foreign entities, with key application dates starting from January 5, 2024, and a closing date of January 7, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-088.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-088-Full-Announcement.html
    PAR-24-088.html
    The National Institutes of Health (NIH) is offering funding through the Notice of Funding Opportunities (NOFO) for the discovery of in vivo chemical probes targeting the nervous system, specifically through the R01 Research Project Grant mechanism. The aim is to support research that focuses on developing novel small molecules that can enhance the understanding of biological processes tied to mental health, aging, addiction, and eye diseases. Applicants are encouraged to have validated starting compounds for optimization and bioassays for testing. The funding covers various areas of research, prioritizing projects that yield insights into disease-related biological targets. Key application dates begin with an opening submission date of January 5, 2024, with subsequent due dates extending into 2026. Eligible applicants include higher education institutions and various nonprofit organizations, as well as foreign entities. NIH emphasizes compliance with the data management and sharing policies introduced in recent notices. The review process will prioritize scientific merit, innovation, and the applicant's experience in relevant research fields. This funding opportunity underscores NIH’s commitment to advancing research into critical health issues through innovative chemical biology approaches.
    Similar Opportunities
    Discovery of in vivo Chemical Probes for the Nervous System
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the discovery of in vivo chemical probes for the nervous system, specifically targeting novel brain mechanisms. This initiative, led by the National Institute on Aging (NIA) in collaboration with the National Eye Institute (NEI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH), seeks applicants who possess validated starting compounds for chemical optimization and bioassays to explore new analog compounds. The focus will be on developing small molecules that can enhance understanding of biological processes relevant to brain diseases, with an emphasis on innovative biological targets. Interested applicants can reach out to Dr. Paul G. Grothaus at grothausp@mail.nih.gov or call 240-688-6634 for further information, with the estimated synopsis posting date set for February 26, 2026, and a projected award date of April 5, 2027.
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research in drug discovery for psychiatric disorders. The initiative focuses on the development and validation of screening assays to identify effective chemical hits for conditions such as depression, bipolar disorder, and schizophrenia, encouraging innovative approaches in mental health research. This grant opportunity is open to a wide range of eligible applicants, including higher education institutions and community-based organizations, with no budget limits and a maximum project period of five years. Interested parties can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications accepted until May 7, 2026.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)." This initiative aims to support the characterization and efficacy studies of neurotherapeutic agents intended for treating neurological disorders, with a focus on conducting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate the biological activity of proposed therapeutic agents. The program emphasizes the importance of rigorous experimental design, collaboration, and the inclusion of diverse perspectives in research teams, aligning with NIH's mission to translate research discoveries into effective therapies. Interested applicants can apply for funding up to $499,000 per year for a total project duration not exceeding three years, with the application deadline set for October 20, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html.
    Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research on the biological mechanisms underlying complex brain disorders such as schizophrenia, bipolar disorder, and autism. This initiative encourages studies that explore high-confidence risk factors associated with these disorders, focusing on intracellular, transcellular, and circuit mechanisms, while emphasizing the importance of disseminating findings to enhance data resources and therapeutic target identification. Eligible applicants include a wide range of institutions, including historically black colleges, tribal colleges, and various nonprofit organizations, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and detailed information can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-024.html.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators" through the National Cancer Institute (NCI). This initiative aims to support research focused on the identification and development of small molecules that can elucidate cancer biology and contribute to therapeutic advancements. The funding is intended for various eligible applicants, including educational institutions and non-profit organizations, with a flexible budget and a project duration of up to three years. Key deadlines include an application submission window starting January 5, 2025, and a closing date of September 7, 2026. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html.
    Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting research grant applications for the development and application of novel positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging ligands aimed at enhancing drug discovery and understanding central nervous system (CNS) disorders. This funding opportunity seeks to stimulate research that evaluates new radioligands capable of assessing molecular targets related to CNS disorders, thereby contributing to the understanding of disease mechanisms and the evaluation of therapeutic candidates. The initiative is particularly significant for advancing neuroimaging techniques, especially in the context of mental health and aging-related conditions. Applications are due starting January 5, 2025, with a maximum project period of five years, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-036.html.
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Blueprint Neurotherapeutics Network (BPN) for small molecule drug discovery and development targeting disorders of the nervous system. This initiative invites applications for cooperative agreements (UG3/UH3) from neuroscience investigators to advance their projects through various stages of drug development, including Discovery and Development phases, while collaborating with NIH-funded consultants and specialized contract research organizations (CROs). The program emphasizes the importance of innovative approaches to treating complex neurological conditions and requires adherence to Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). Interested applicants can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications due by August 18, 2026.
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Blueprint Neurotherapeutics Network (BPN) aimed at advancing small molecule drug discovery and development for disorders of the nervous system. This cooperative agreement invites applications from neuroscience researchers to conduct exploratory and developmental phases of drug development, allowing them to retain intellectual property rights while collaborating with NIH consultants and contract research organizations. The program is designed to facilitate the optimization and testing of drug candidates, adhering to regulatory standards and promoting diversity in research teams, ultimately seeking innovative therapeutic solutions for conditions aligned with NIH institutes such as NINDS, NIA, and NIMH. Interested applicants should prepare comprehensive applications, with key deadlines including a close date of August 18, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Research Project Grants (R01) aimed at the development of screening assays for drug candidates targeting psychiatric disorders. The primary objectives of this initiative are to stimulate research in the discovery and development of novel small molecules that can potentially treat mental illnesses, as well as to validate compounds that demonstrate desired biological activity through rigorous screening processes. This funding is crucial for advancing therapeutic options for conditions such as depression, schizophrenia, and PTSD, and it encourages applicants to align their proposals with the National Institute of Mental Health (NIMH) priorities. Interested applicants must submit their proposals by May 7, 2026, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.